{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:57:34Z","timestamp":1785275854554,"version":"3.55.0"},"reference-count":65,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>A combination of cytoreductive surgery, either primary (PCS) or interval (ICS), and chemotherapy with a platinum-paclitaxel regimen is the well-accepted treatment for advanced-stage epithelial ovarian cancer (EOC), fallopian tube cancer (FTC), and primary peritoneal serous carcinoma (PPSC), but it is still uncertain whether a combination of dose-dense weekly paclitaxel and low-dose triweekly cisplatin is useful in the management of these patients. Therefore, we retrospectively evaluated the outcomes of women with advanced-stage EOC, FTC, and PPSC treated with PCS and subsequent dose-dense weekly paclitaxel (80 mg\/m2) and low-dose triweekly cisplatin (20 mg\/m2). Between January 2011 and December 2017, 32 women with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC\u2013IV EOC, FTC, or PPSC were enrolled. Optimal PCS was achieved in 63.5% of patients. The mean and median progression-free survival was 36.5 and 27.0 months, respectively (95% confidence interval (CI): 26.8\u201346.2 and 11.3\u201342.7 months, respectively). The mean overall survival was 56.0 months (95% CI: 43.9\u201368.1 months), and the median overall survival could not be obtained. The most common all-grade adverse events (AEs) were anemia (96.9%), neutropenia (50%), peripheral neuropathy (28.1%), nausea and vomiting (34.4%), and thrombocytopenia (15.6%). These AEs were predominantly grade 1\/2, and only a few patients were complicated by grade 3\/4 neutropenia (21.9%) and anemia (6.3%). A multivariate analysis indicated that only suboptimal PCS was significantly correlated with a worse prognosis, resulting in an 11.6-fold increase in the odds of disease progression. In conclusion, our data suggest that dose-dense weekly paclitaxel (80 mg\/m2) combined with low-dose triweekly cisplatin (20 mg\/m2) is a potentially effective and highly tolerable front-line treatment in advanced EOC, FTC, and PPSC. Randomized trials comparing the outcome of this regimen to other standard therapies for FIGO stage IIIC\u2013IV EOC, FTC, and PPSC are warranted.<\/jats:p>","DOI":"10.3390\/ijerph16234794","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T10:58:21Z","timestamp":1575025101000},"page":"4794","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer"],"prefix":"10.3390","volume":"16","author":[{"given":"Min","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard Hao","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hsun","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan"},{"name":"Department of Nursing, Taipei Veterans General Hospital, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na-Rong","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan"},{"name":"Department of Nursing, Taipei Veterans General Hospital, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yi","family":"Huang","sequence":"additional","affiliation":[{"name":"Biostatics Task Force, Taipei Veterans General Hospital, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei 112, Taiwan"},{"name":"Institute of Clinical Medicine, National Yang-Ming University, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huann-Cheng","family":"Horng","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ling","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cheng-Hsin General Hospital, Taipei 112, Taiwan"},{"name":"Department of Nursing, Oriental Institute of Technology, New Taipei City 220, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-8541","authenticated-orcid":false,"given":"Peng-Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 112, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Yang-Ming University, Taipei 112, Taiwan"},{"name":"Institute of Clinical Medicine, National Yang-Ming University, Taipei 112, Taiwan"},{"name":"Department of Medical Research, China Medical University Hospital, Taichung 440, Taiwan"},{"name":"The Female Cancer Foundation, Taipei 104, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_3","first-page":"144","article-title":"Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer","volume":"13","author":"Piccart","year":"2003","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_4","first-page":"88","article-title":"Carboplatin versus cisplatin in ovarian cancer","volume":"22","author":"Alberts","year":"1995","journal-title":"Semin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1008365929809","article-title":"First-line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer\u2014a new standard of care?","volume":"10","author":"Neijt","year":"1999","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"Luck","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tjog.2018.02.015","article-title":"The role of \u03b12,3-linked sialylation on clear cell type epithelial ovarian cancer","volume":"57","author":"Sung","year":"2018","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(19)30178-0","article-title":"Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3\/ENGOT-ov2\/GOG-3001): A randomised, double-blind, phase 3 trial","volume":"20","author":"Vergote","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Coleman, R.L., Fleming, G.F., Brady, M.F., Swisher, E.M., Steffensen, K.D., Friedlander, M., Okamoto, A., Moore, K.N., Efrat Ben-Baruch, N., and Werner, T.L. (2019). Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1909707"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","article-title":"The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer","volume":"332","author":"Buyse","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.tjog.2018.08.006","article-title":"Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal\/ovarian cancer patients","volume":"57","author":"Kusunoki","year":"2018","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.tjog.2018.08.001","article-title":"Neoadjuvant chemotherapy before definite operative approach for women with advanced-stage epithelial ovarian cancer","volume":"57","author":"Wang","year":"2018","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ygyno.2019.07.011","article-title":"A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy","volume":"154","author":"Bartels","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2019.05.023","article-title":"Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy","volume":"154","author":"Horner","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Klein, D.A., Mann, A.K., Freeman, A.H., Liao, C.I., Kapp, D.S., and Chan, J.K. (2019). Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed?. Am. J. Obstet. Gynecol.","DOI":"10.1016\/j.ajog.2019.07.050"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Southwest Oncology, Oncology G. Gynecologic, Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial","volume":"21","author":"Markman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.critrevonc.2019.01.002","article-title":"Role of intraperitoneal chemotherapy in ovarian cancer in the platimum-taxane-based era: A meta-analysis","volume":"136","author":"Marchetti","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ygyno.2019.08.024","article-title":"Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer","volume":"155","author":"Vergote","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.critrevonc.2019.08.002","article-title":"Hopes and failures in front-line ovarian cancer therapy","volume":"143","author":"Tsibulak","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bpobgyn.2019.03.005","article-title":"Immunotherapy of gynecological cancers","volume":"60","author":"Matanes","year":"2019","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2019.02.008","article-title":"Phase III trials in ovarian cancer: The evolving landscape of front line therapy","volume":"153","author":"Coleman","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Feng, Y., Huang, H., Wan, T., Zhang, C., Tong, C., and Liu, J. (2019). Comparison of PARPis with angiogenesis inhibitors and chemotherapy for maintenance in ovarian cancer: A network meta-analysis. Adv. Ther.","DOI":"10.1007\/s12325-019-01106-1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.tjog.2017.08.026","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer","volume":"56","author":"Liu","year":"2017","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Chang, C.M., Yang, Y.P., Chuang, J.H., Chuang, C.M., Lin, T.W., Wang, P.H., Yu, M.H., and Chang, C.C. (2017). Discovering the deregulated molecular functions involved in malignant transformation of endometriosis to endometriosis-associated ovarian carcinoma using a data-driven, function-based analysis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112345"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.tjog.2016.06.004","article-title":"Gene set-based integrative analysis of ovarian clear cell carcinoma","volume":"55","author":"Chang","year":"2016","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.tjog.2016.12.016","article-title":"Gene se-based analysis of mucinous ovarian carcinoma","volume":"56","author":"Chang","year":"2017","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chang, C.C., Su, K.M., Lu, K.H., Lin, C.K., Wang, P.H., Li, H.Y., Wang, M.L., Lin, C.K., Yu, M.H., and Chang, C.M. (2018). Key immunological functions involved in the progression of epithelial ovarian serous carcinoma discovered by the gene ontology-based immunofunctionome analysis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113311"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ncponc0560","article-title":"The Norton-Simon hypothesis: Designing more effective and less toxic chemotherapeutic regimens","volume":"3","author":"Simon","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tjog.2012.04.002","article-title":"Metronomic therapy for gynecologic cancers","volume":"51","author":"Su","year":"2012","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_43","first-page":"e000117","article-title":"Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: A retrospective study of feasibility and efficacy","volume":"1","author":"Milani","year":"2017","journal-title":"ESMO Open"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"viii36","DOI":"10.1093\/annonc\/mdx450","article-title":"Front-line therapy of advanced epithelial ovarian cancer: Standard treatment","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.3802\/jgo.2018.29.e96","article-title":"Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: Which is the optimal adjuvant chemotherapy regimen?","volume":"29","author":"Lee","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s10147-018-1264-9","article-title":"Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status","volume":"23","author":"Takaya","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.critrevonc.2018.02.016","article-title":"Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials","volume":"125","author":"Marchetti","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Shibutani, T., Nagao, S., Suzuki, K., Kaneda, M., Yamamoto, K., Jimi, T., Yano, H., Kitai, M., Shiozaki, T., and Matsuoka, K. (2019). Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: A retrospective study. Int. J. Clin. Oncol.","DOI":"10.1007\/s10147-019-01567-y"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Huang, B.S., Chang, W.H., Wang, K.C., Huang, N., Guo, C.Y., Chou, Y.J., Huang, H.Y., Chen, T.J., Lee, W.L., and Wang, P.H. (2016). Endometriosis might be inversely associated with developing chronic kidney disease: A population-based cohort study in Taiwan. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17071079"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e0157","DOI":"10.1097\/MD.0000000000010157","article-title":"Risks of female genital tract related cancers (gynecological cancers) or breast cancer in women with and without chronic kidney disease: A population-based cohort study in Taiwan","volume":"97","author":"Chang","year":"2018","journal-title":"Medicine"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Fiseha, T., Mengesha, T., Girma, R., Kebede, E., and Gebreweld, A. (2019). Estimation of renal function in adult outpatients with normal serum creatinine. BMC Res. Notes, 12.","DOI":"10.1186\/s13104-019-4487-6"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e10070","DOI":"10.2196\/10070","article-title":"Software for administering the National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study","volume":"5","author":"Schoen","year":"2018","journal-title":"JMIR Hum. Factors"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jamia\/ocy169","article-title":"Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute\u2019s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"26","author":"Chung","year":"2019","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Raimondi, A., Randon, G., Sepe, P., Claps, M., Verzoni, E., de Braud, F., and Procopio, G. (2019). The evaluation of response to immunotherapy in metastatic renal cell carcinoma: Open challenges in the clinical practice. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174263"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41416-019-0543-1","article-title":"Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: A randomised controlled study","volume":"121","author":"Shi","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2019.04.005","article-title":"Total and out-of-pocket costs of different primary management strategies in ovarian cancer","volume":"221","author":"Suidan","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_57","first-page":"629378","article-title":"Anti-angiogenesis therapy in ovarian cancer: Which patient is it most likely to benefit?","volume":"33","author":"Coleman","year":"2019","journal-title":"Oncology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN guidelines insights: Ovarian cancer, version 1.2019","volume":"17","author":"Armstrong","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"AGO Study Group led Gynecologic Cancer Intergroup\/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"Kristensen","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"Floquet","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Boussios, S., Karihtala, P., Moschetta, M., Karathanasi, A., Sadauskaite, A., Rassy, E., and Pavlidis, N. (2019). Combined strategies with poly (ADP-Ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: A literature review. Diagnostics, 9.","DOI":"10.3390\/diagnostics9030087"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1158\/1078-0432.CCR-19-0619","article-title":"Advancing drug development in gynecologic malignancies","volume":"25","author":"Beaver","year":"2019","journal-title":"Clin. Cancer Res."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/16\/23\/4794\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:38:36Z","timestamp":1760189916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/16\/23\/4794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":65,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["ijerph16234794"],"URL":"https:\/\/doi.org\/10.3390\/ijerph16234794","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]}}}